跳至主要内容
临床试验/NCT05368909
NCT05368909已完成不适用

Assessment of the Effects of a Dietary Supplement on the Sleep Health and Sleep Quality of People With Sleep Problems: A Randomized, Double-blind, Placebo-controlled, Crossover Design Study

4Life Research, LLC2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2021年12月16日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
2
主要终点
Saliva Melatonin level changes

研究概览

简要总结

The primary objective of this study is to evaluate the effects of a proprietary oral supplement on the sleep health and quality of people with sleep problems. It is a double-blinded placebo-controlled crossover clinical study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Non-smokers
  • Judged by the Investigator to be in general good health on the basis of medical history
  • Willing to wash out of all dietary supplements, essential oils, and non-prescription sleep aids or Rx sleep aids for the duration of the study
  • Insomnia Severity Index score of ≥ 8
  • Must agree to maintain the same eating, exercise, and sleep arrangements for the whole duration of the study

排除标准

  • Pregnant and/or lactating women
  • Known allergy or adverse reaction to ingredients in the product: Tri Factor (bovine colostrum and egg yolk extracts), Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) or Magnesium
  • Prescription sedative or psychoactive (including anti-depressant) medication use
  • Diagnosis of a sleep disorder (e.g., sleep apnea, periodic limb movement disorder, etc.) or high clinical probability of another sleep disorder based on sleep history
  • A clinically unstable medical condition as defined by a new diagnosis or change in medical management in the previous 4 months (e.g., myocardial infarction, congestive heart failure, Cheyne-Stokes breathing, unstable angina, thyroid disease, depression or psychosis, ventricular arrhythmias, cirrhosis, surgery, or recently diagnosed cancer)
  • Routine consumption of more than 2 alcoholic beverages per day or consumption of caffeine past 2 PM for the duration of the study
  • Illicit drug use
  • Use of prescription stimulants (modafinil, dextroamphetamine, etc.)
  • Use of prescription medications known to affect sleep (antidepressants, anti-anxiety, opioids, alpha-blockers, beta-blockers, corticosteroids, ACE inhibitors, angiotensin II-receptor blockers, cholinesterase inhibitors, allergy medication, asthma medication, glucosamine and chondroitin, statins, anti-smoking or thyroid medication, muscle relaxants, anticonvulsants)
  • Unable to perform tests due to inability to communicate verbally, inability to write and read in English; less than a 10th grade reading level; visual, hearing or upper extremity motor deficit
  • Night shift workers in situations or occupations where they regularly experience jet lag, or have irregular work schedules by history over the last 6 months
  • Unwilling to consume or unable to swallow capsules/tablets
  • Previous exposure to this product in earlier testing phases

结局指标

主要结局

Saliva Melatonin level changes

时间窗: 6 weeks

Samples taken before bedtime at night and 2 hours after wakeup the next morning. A total of 8 samples were taken for each subject: (2) right after first washout, (2) right after Arm 1, (2) right after the second washout, (2) right after Arm 2.

Insomnia Severity Index Score

时间窗: 6 weeks

A scale used to measure the severity of insomnia. Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)

次要结局

  • Sleep Onset Latency(6 weeks)
  • Total Sleep Time(6 weeks)
  • Leeds Sleep Evaluation Questionnaire (LSEQ) Score(6 weeks)
  • Sleep Efficiency(6 weeks)

研究者

发起方
4Life Research, LLC
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验